NVSNovartis AG

$143.73+20% 1Y

$143.73

$118.2052 weeks$163.64

Is the price fair?

Mixed

Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 neutral, 2 without data

What the price assumes~+4% a yearderived · Jun 30, 2025

Priced for ~4% a year FCF growth. Roughly in line with its three-year revenue growth of 5% a year.

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What NVS's price assumes

Novartis AG trades at 21.2× earnings against 26.2× for the median Drug Manufacturers - General name, cheaper than its own group.

21.2

Trailing P/E · Drug Manufacturers - General median 26.2 · cheaper than the typical name in its group

Price / sales: 3.17
Price / sales · as of 2025-H2
Free cash flow yield: 5.5%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: +4.3%
Growth the price implies · The price pays for +4.3% free cash flow growth a year for a decade; the business has delivered +15% a year over the last three.